Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Jul 28, 2014; 20(28): 9253-9260
Published online Jul 28, 2014. doi: 10.3748/wjg.v20.i28.9253
Published online Jul 28, 2014. doi: 10.3748/wjg.v20.i28.9253
Table 3 Preliminary data on virological response during triple therapy in post-liver transplantation
| Verna et al[49] | Aqel et al[50] | McCashland et al[51] | Burton et al[52] | Kwo et al[53] | de Oliviera et al[54] | |
| Patients (n) | 101 | 23 | 10 | 12 | 7 | 6 |
| Regimen | ||||||
| BCV | 10 | 23 | 0 | 0 | 0 | 0 |
| TVL | 91 | 0 | 10 | 12 | 7 | 6 |
| Four-week lead-in phase | 96% | 100% | NA | 100% | 100% | NA |
| Fibrosis | ||||||
| F0–F2 | 58 | NA | 7 | 8 | 5 | NA |
| F3–F4 | 43 | NA | 3 | 4 | 2 | NA |
| Cholestatic hepatitis (n) | 10 | NA | NA | NA | 7 | NA |
| IS therapy | ||||||
| TAC | 23 | 0 | 0 | 0 | 2 | 6 |
| CSA | 67 | 23 | 10 | 12 | 5 | 0 |
| HCV genotype | 1 | 1 | 1 | 1 | 1 | 1 |
| HCV-RNA negative | ||||||
| Week 4 | 70% (64/92) | 43% (10/23) | 22% (2/9) | 92% (11/12) | 29% (2/7) | NA |
| Week 8 | 78% (61/78) | NA | NA | NA | 71% (5/7) | NA |
| Week 12 | 79% (68/86) | NA | 100% (3/3) | NA | NA | 33% (1/3) |
| Week 24 | NA | 17% (4/23) | 100% (1/1) | NA | NA | NA |
- Citation: Dall’Agata M, Gramenzi A, Biselli M, Bernardi M. Hepatitis C virus reinfection after liver transplantation: Is there a role for direct antiviral agents? World J Gastroenterol 2014; 20(28): 9253-9260
- URL: https://www.wjgnet.com/1007-9327/full/v20/i28/9253.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i28.9253